PROFILPELAJAR.COM

6-Isopropyl-6-nor-lysergic acid diethylamide
Clinical data
Routes of; administration	Oral
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class A;
Identifiers
	IUPAC name (6aR,9R)-N,N-Diethyl-7-propan-2-yl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;
PubChem CID	44458092;
ChemSpider	23120596;
ChEMBL	ChEMBL22893;
Chemical and physical data
Formula	C22H29N3O
Molar mass	351.494 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C(C)C;
	InChI InChI=1S/C22H29N3O/c1-5-24(6-2)22(26)16-10-18-17-8-7-9-19-21(17)15(12-23-19)11-20(18)25(13-16)14(3)4/h7-10,12,14,16,20,23H,5-6,11,13H2,1-4H3/t16-,20-/m1/s1; Key:GLNOSFGSNDKLOC-OXQOHEQNSA-N;
	(verify)

6-Isopropyl-6-nor-lysergic acid diethylamide (IP-LAD) is an analog of lysergic acid diethylamide (LSD) developed by the team of David E. Nichols. In studies on mice, it was found to be approximately 40% the potency of LSD, compared to the 60% increase in potency seen with ETH-LAD, 2-fold potency increase of AL-LAD, and roughly equivalent potency of PRO-LAD.^[1]

References

^ Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–1255. doi:10.1021/jm00147a022. PMID 4032428.